ROCHESTER, New York, September 18 /PRNewswire/ --

- Lesions non-invasively imaged in 5 to 10 minutes

- Landmark Study Reported in Journal of Investigative Dermatology

A landmark publication that appeared in the Journal of Investigative
Dermatology reports the results of a large, two site blinded clinical study.
The paper is entitled "The Impact of In Vivo Reflectance Confocal Microscopy
for the Diagnostic Accuracy of Melanoma and Equivocal Melanocytic Lesions."

The study, lead by Dr. Giovanni Pellacani, contained a total of 351
equivocal melanocytic lesions that were difficult for expert dermoscopists to
diagnose. 136 of the 351 lesions were malignant melanomas. The highest
sensitivity demonstrated by confocal microscopy was 96.3%. The highest
accuracy corresponded to a sensitivity of 91.9% and a specificity of 69.3%.
The standard of comparison for the study was biopsy of all 351 lesions,
followed by traditional pathological examination.

"By giving reliable diagnostic information comparable to histology,
confocal imaging represents the only feasible alternative to biopsy in the
decision-making process faced by dermatologists examining melanocytic
lesions," said Dr. Giovanni Pellacani, Department of Dermatology, University
of Modena and Reggio Emilia, Modena, Italy, one of the world's leading
in-vivo confocal imaging medical researchers. "Consequently, in vivo confocal
microscopy is used at Modena and in several other melanoma clinics in Europe
for the analysis of melanocytic lesions," Dr. Pellacani continued.

Images Acquired from Lucid VivaScopes(R) in 5 to 10 minutes

"The images in this study were acquired using VivaScope(R) confocal
microscopes developed and manufactured by Lucid Inc., of Rochester, New
York," said Jay Eastman, Ph.D., Chairman and CEO of Lucid, Inc. "This study
represents a major clinical milestone in the transition of confocal imaging
from a basic research tool to a diagnostic medical device being used
routinely for evaluation of melanocytic lesions. Imaging a single lesion
using the VivaScope(R) required just 5 to 10 minutes according to the
authors," continued Eastman, "which makes it practical for everyday use in
private dermatology practices worldwide."

Study Detailed in the Journal of Investigative Dermatology

The entire paper recounting the study can be found in the Journal of
Investigative Dermatology (2007), 0, 000-000, doi: 10.1038/sj.jid.5700993,
"The Impact of In Vivo Reflectance Confocal Microscopy for the Diagnostic
Accuracy of Melanoma and Equivocal Melanocytic Lesions," authors Giovanni
Pellacani, Pascale Guitera, Caterina Longo, Michelle Avramidis, Stefania
Seidenari and Scott Menzies. On the Web, visit
http://dx.doi.org/10.1038/sj.jid.5700993 .

Authors Pellacani, Longo, and Seidenari are of the Department of
Dermatology, University of Modena and Reggio Emilia, Modena, Italy. Guitera,
Avramidis, and Menzies are of the Faculty of Medicine, Sydney Melanoma
Diagnostic Centre, Sydney Cancer Centre and Dermatology Department, Royal
Prince Alfred Hospital, University of Sydney, Sydney, Australia.

This paper builds on the results of an earlier pilot study that was
published in the December 2005 issue of the Journal of the American Academy
of Dermatology, beginning on page 979 of that issue.

About Lucid Inc.

Lucid Inc., based in Rochester, New York, USA, is a medical device and
information company dedicated to creating innovative cellular imaging
technology and using the Internet to securely deliver accurate, real-time
VivaScope(R) cellular resolution images to medical professionals. When
coupled with its digital VivaNet(TM) system, the company's ability to image
in-vivo (living) tissue will aid medical practitioners and pathologists in
skin cancer screening with clarity, speed and patient comfort. For more
information about Lucid Inc., visit http://www.Lucid-tech.com .

Available Topic Expert(s): For information on the listed expert(s), click
    appropriate link.
    Jay Eastman, Ph.D.
    http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=62055



Web site: http://www.Lucid-tech.com